Cytokinetics' (CYTK) Q1 Results Solid, BENEFIT Remains in Focus - Roth

May 7, 2014 9:29 AM

Roth Capital has Cytokinetics (Nasdaq: CYTK) at Buy with a target price of $13 following Q1 results.After markets closed Tuesday ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found